PrecivityAD2 testing gives a blood-based estimate of amyloid likelihood, not a diagnosis of Alzheimer's dementia. If you have mild cognitive impairment, avoid overreading the headline by treating a positive as a reason for specialist follow-up, not a forecast of decline.
It is cleared for adults 40 and older with symptoms and used alongside clinical assessment, according to the Alzheimer's Association in its clearance announcement. Mild cognitive impairment means noticeable change beyond age norms but below dementia. That gap is where headlines mislead.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the clearance actually means
- How strong a positive or negative really is
- Why mild impairment needs extra caution
- What to do after your result
What the clearance actually means
The result is one piece of an exam, not a stand-alone answer. A clinician experienced in cognitive evaluation pairs it with history, thinking tests, and other medical checks.
Ordering outside that process or reading it alone goes beyond its cleared use. A useful visit tracks change over time. Bring a timeline of symptoms, a complete medicine list, and someone who sees your daily function.
How strong a positive or negative really is
Validation measured blood calls against amyloid PET or spinal-fluid results. Clear results were strong.
Positives showed 97.6% positive predictive value and negatives 93.1% negative predictive value in a 1,142-person symptomatic cohort, while about 17.3% fell intermediate with 77.3% positive predictive value, according to NeurologyLive in its accuracy summary. Give most weight to a clear positive or clear negative. Give less weight to a near-cutoff likely-positive result and ask what confirmatory step fits.
Why mild impairment needs extra caution
Mild impairment sits between normal aging and dementia. It does not always move forward. About 20% in cited cohorts develop non-Alzheimer dementias or do not progress, per the International Journal of Molecular Sciences in its cohort review.
Amyloid can appear when memory issues have another driver or stay stable. So match the blood result to the clinical picture, not the reverse. Ask whether sleep, mood, vascular risks, or medicines better explain the change.
What to do after your result
A positive points toward Alzheimer-related pathology and can speed workup or trial referral. A positive signals Alzheimer-associated pathology and can speed specialist workup or trial referral, but does not by itself diagnose Alzheimer's dementia or predict when conversion will occur, according to Medical News Today in its clearance report.
Use the appointment to pin down category and next steps. Small questions prevent large misreadings.
- Ask which category your score falls in: negative, positive, or intermediate likely-positive.
- Ask what confirmatory test, if any, fits your symptoms and plans.
- Ask what reversible contributors were ruled out and when follow-up is set.
You Might Also Like
- Subjective Cognitive Decline Data for Public Health Action in 2026: A Source-Checked Briefing for Adults in Midlife
- Dementia Subtype Data Gaps Identified by NIA in 2026: Who Was Studied and Who Was Not for Adults With Memory Concerns
- Questions to Ask About Music Practice for Brain Health With Mild Cognitive Impairment
